|
BMC Cancer 2008
Immunohistochemical profiling of benign, low malignant potential and low grade serous epithelial ovarian tumorsAbstract: In the present study, we used a tissue array composed of 27 BOVs, 78 LMPs and 23 LG TOVs to evaluate the protein expression of a subset of selected candidates identified in our previous studies (Ape1, Set, Ran, Ccne1 and Trail) or known to be implicated in epithelial ovarian cancer disease (p21, Ccnb1, Ckd1).Statistically significant difference in protein expression was observed for Ccnb1 when BOV tumors were compared to LMP tumors (p = 0.003). When BOV were compared to LG TOV tumors, Trail was significantly expressed at a higher level in malignant tumors (p = 0.01). Expression of p21 was significantly lower in LG tumors when compared with either BOVs (p = 0.03) or LMPs (p = 0.001). We also observed that expression of p21 was higher in LMP tumors with no (p = 0.02) or non-invasive (p = 0.01) implants compared to the LMP associated with invasive implants.This study represents an extensive analyse of the benign and highly differentiated ovarian disease from an immunohistochemical perspective.Tumors of the ovary represent a large, heterogeneous and complex group of neoplasms. The majority of these tumors are derived from ovarian surface epithelial cells, from epithelial inclusion cysts confined in the stroma or from the epithelium of the fallopian tube [1,2]. Epithelial ovarian tumors present as different histopathology subtypes among which the serous subtype is the most frequent [reviewed in [3,4]].Serous tumors can be subdivided into benign (BOV), borderline or low malignant potential (LMP) and invasive (TOV) tumors. BOV tumors are characterized by epithelial proliferation without any stratification of cells. LMP tumors are distinguished from their benign counterpart by the complexity of their architecture and the presence of epithelial budding. LMP tumors show a pluristratified proliferation of the epithelium. LMP tumor cells exhibit some nuclear atypia and show a higher mitotic activity when compared to BOV [reviewed in [5-9]].In contrast to BOV and LMP tumors, TOV
|